New progress in targeted treatment of cholangiocarcinoma: pemetinib/pemetinib and other drugs

The field of targeted drug treatment of cholangiocarcinoma (CCA) has made significant progress in recent years, with a variety of new drugs and treatment strategies emerging, providing patients with more treatment options. Although there is currently no fixed list of the "latest five targeted drugs", there are some drugs that have shown good efficacy and safety in clinical trials and practical applications.

Pemigatinib/Pemigatinib is one of the targeted drugs that has attracted much attention. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2020, becoming the first FGFR inhibitor targeted therapy for cholangiocarcinoma. Pemetinib is a tyrosine kinase inhibitor used to treat cholangiocarcinoma. It inhibits the growth and spread of tumor cells by inhibiting the activity of tyrosine kinases in tumor cells and interfering with cell signaling.

In multi-center clinical trials such as FIGHT-202, pemetinib has demonstrated a high objective response rate and median response duration in patients with cholangiocarcinoma with FGFR2 gene fusion. Although the drug may be associated with some side effects, overall it provides a new treatment option for patients with cholangiocarcinoma.

In addition to pemetinib, there are several othersFGFR inhibitors are also under research and application, such as erdafitinib, infitinib, and derazantinib. These drugs inhibit the FGFR signaling pathway through different mechanisms, thereby inhibiting the growth and spread of tumor cells. They have shown varying degrees of efficacy and safety in clinical trials at different stages and are expected to provide more treatment options for patients with cholangiocarcinoma. In addition, targeted drugs and VEGF inhibitors targeting IDH1/2 mutations also play an important role in the treatment of cholangiocarcinoma. These drugs are expected to improve patients' survival and quality of life by targeting different molecular mechanisms and pathological characteristics of cholangiocarcinoma.

The treatment of cholangiocarcinoma is an individualized process, and doctors will develop personalized treatment plans based on the patient's specific conditions. When choosing targeted drug therapy, doctors will consider multiple factors, including the genetic mutation of the tumor, the patient's overall health, and previous treatment history. At the same time, patients also need to closely cooperate with doctors’ treatment recommendations and communicate in a timely manner about treatment effects and adverse reactions so that doctors can make adjustments and management based on the actual situation.

In short, with the continuous development of the field of targeted drug treatment of cholangiocarcinoma, more and more new drugs and treatment strategies will bring more hope and opportunities to patients. However, each patient's treatment response and effectiveness may vary based on individual differences, so individualized treatment plans and comprehensive management are crucial.